期刊文献+

小儿非霍奇金淋巴瘤的诊断及预后分析

Diagnosis and prognosis of children with non-Hodgkin lymphoma
原文传递
导出
摘要 目的探讨小儿非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)的临床表现及预后危险因素。方法收集2006年3月至2012年10月期间初治的81例NHL患儿的资料。采用Kaplan-Meier进行生存分析,统计5年总生存率及无复发生存率。采用卡方检验分析不同临床因素与生存率的关系。采用多因素Logistic回归分析NHL的预后危险因素。结果 81例患儿包括23例前驱淋巴母细胞型,11例成熟T/NK淋巴细胞型,47例成熟B淋巴细胞型;其中以Burkitt淋巴瘤所占比例最高(35.80%)。前驱淋巴母细胞肿瘤患儿主要以外周淋巴结肿大(43.78%)为首发表现;成熟T/NK淋巴细胞肿瘤患儿主要以纵隔受累(45.45%)为首发表现;成熟B细胞肿瘤患儿中,29例Burkitt淋巴瘤患儿主要以腹腔受累(41.40%)为首发表现,15例弥漫性大细胞淋巴瘤患儿以腹部肿块(60.00%)为首发表现。77例患儿(4例放弃治疗)经治疗后,90.91%完全缓解,5.19%部分缓解,2.60%治疗后复发,1.30%出现中枢神经系统浸润。76例患者完成随访,5年的总生存率为67.11%,5年无复发生存率为63.16%。B症状、乳酸脱氢酶水平、临床分期是影响患儿5年总生存率及无复发生存率的因素(P均<0.05)。乳酸脱氢酶(LDH)≥500 U/L(OR:3.294)、临床晚期(Ⅳ期)(OR:2.756)是影响患儿预后的独立危险因素(P<0.05)。结论儿童NHL的临床表现呈多样化,LDH水平及临床分期是影响预后的独立危险因素,可以为早期治疗提供一定的参考。 Objective To explore the clinical features and risk factors influencing the prognosis of childhood non-hodgkin's lymphoma( NHL). Methods Pathologically diagnosed 81 pediatric patients with NHL and treated in our hospital from March 2006 to October 2012 were collected and analyzed. The 5-years overall survival rate and replace-free survival rate were calculated and analyzed by Kaplan-Meier method. The relationship between survival rates and different factors were analyzed using chi-square test. Logistic analysis were used to analyze risk factors of prognosis.Results Totally 81 pediatric patients with NHL included 23 cases of lymphoblastic lymphoma,11 cases of mature T/NK-cell tumor,and 47 cases of mature B-cell tumor,Burkitt lymphoma was the most common( 35. 80%). Swelling of periphery lymph node( 43. 78%),mediastinal involvement( 45. 45%) were observed as initial symptom in lymphoblastic lymphoma and mature T/NK-cell tumor,respectively. Among mature B-cell tumor,the main clinical feature of abdominal cavity( 41. 40%) was observed in 29 cases of Burkitt lymphoma,and abdominal mass( 60. 00%) was observed as initial symptom in diffuse large cell lymphoma. 77 pediatric patients with NHL( 4 cases withdrawing treatment) received treatments were found that 90. 5% attained complete remission( CR),5. 19% attained partial remission( PR),2. 60% rapidly relapsed after treatment,and 1. 30% appeared the central nervous system infiltration. 76 pediatric patients with NHL were finished the follow up. The 5-years overall survival rate was 67. 11%. The 5-years replace-free survival rate was 63. 16%. B symptoms,the level of lactate dehydrogenase( LDH),and clinical stages were the influence factors of 5-years overall survival rate and replace-free survival rate( P 0. 05). LDH≥500 U/L( OR: 3. 294) and late stage(Ⅳ) were the independent risk factors of prognosis( P 0. 05). Conclusion Clinical features of pediatric patients with NHL were variable. The level of LDH and late stage(Ⅳ) are independent risk factors of prognosis,which can provide some reference in early treatment.
出处 《医药论坛杂志》 2017年第9期10-13,共4页 Journal of Medical Forum
基金 国家自然科学基金资助项目(81470365)
关键词 儿童非霍奇金淋巴瘤 预后 危险因素 乳酸脱氢酶 临床分期 Children with non- hodgkin lymphoma Prognosis Risk factor Lactate dehydrogenase Clinical stages
  • 相关文献

参考文献4

二级参考文献48

  • 1张永红.儿童非霍奇金淋巴瘤[J].白血病.淋巴瘤,2008,17(1). 被引量:4
  • 2顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 3Brugibres L, Le Deley MC, Rosolen A, et al. Impact of themethotrexate administration dose on the need for intratheeal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the E1CNHL Group. J Clin Onco1,2009,27 : 897-903.
  • 4Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non- l-Iodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin- Frankfurt-Munster Group Trial NHL-BFM 90. Blood, 2001,97: 3699-3706.
  • 5Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood, 2000,95:416-421.
  • 6Sandlund JT, Pui CH, Zhou Y, et al. Effective treatment of advanced-stage childhood |ymphoblastie lymphoma v,,ithout prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia ,2009,23 : 1127-1130.
  • 7Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage Ⅲ or IV lymphoblastic lymphoma. J Clin 0ncol,2006,24:491- 499.
  • 8Mann G, Altarbaschi A, Steiner M, et al. Early and reliable diagalosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorpholog7 and flow cytometric immunophenotyping. Pediatr Hematol Oncol,2006,23:167-176.
  • 9Swerdlow SH, Campo E, Harris NL, et al. Patholog? and geneticsof tumours of hematopoietic and lymphoid tissues. World Health Organization classification of tumours ( ed 4th). Lyon :International Agency for Research on Cancer Press, 2008:270-299.
  • 10Micheal P. Link and Howard Weinstein. Malignant Non-Hodgkin lymphoma in Principle and Practice of Pediatric Oncology. Philip A Pizzo, David G Poplock. 5th ed. Philadelphia. New York: LWW. corn ,2006:722-747.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部